Literature DB >> 20959465

The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.

Kyung-Soo Chun1, Huei-Chen Lao, Robert Langenbach.   

Abstract

The prostaglandin E(2) (PGE(2)) G protein-coupled receptor (GPCR), EP2, plays important roles in mouse skin tumor development (Chun, K. S., Lao, H. C., Trempus, C. S., Okada, M., and Langenbach, R. (2009) Carcinogenesis 30, 1620-1627). Because keratinocyte proliferation is essential for skin tumor development, EP2-mediated signaling pathways that contribute to keratinocyte proliferation were investigated. A single topical application of the EP2 agonist, butaprost, dose-dependently increased keratinocyte replication via activation of epidermal growth factor receptor (EGFR) and PKA signaling. Because GPCR-mediated activation of EGFR can involve the formation of a GPCR-β-arrestin-Src signaling complex, the possibility of a β-arrestin1-Src complex contributing to EP2-mediated signaling in keratinocytes was investigated. Butaprost induced β-arrestin1-Src complex formation and increased both Src and EGFR activation. A role for β-arrestin1 in EP2-mediated Src and EGFR activation was demonstrated by the observation that β-arrestin1 deficiency significantly reduced Src and EGFR activation. In agreement with a β-arrestin1-Src complex contributing to EGFR activation, Src and EGFR inhibition (PP2 and AG1478, respectively) indicated that Src was upstream of EGFR. Butaprost also induced the activation of Akt, ERK1/2, and STAT3, and both β-arrestin1 deficiency and EGFR inhibition (AG1478 or gefitinib) decreased their activation. In addition to β-arrestin1-dependent EGFR activation, butaprost increased PKA activation, as measured by phospho-GSK3β (p-GSK3β) and p-cAMP-response element-binding protein formation. PKA inhibition (H89 or R(P)-adenosine-3',5'-cyclic monophosphorothioate (R(P)-cAMPS)) decreased butaprost-induced cAMP-response element-binding protein and ERK activation but did not affect EGFR activation, whereas β-arrestin1 deficiency decreased EGFR activation but did not affect butaprost-induced PKA activation, thus indicating that they were independent EP2-mediated pathways. Therefore, the results indicate that EP2 contributed to mouse keratinocyte proliferation by G protein-independent, β-arrestin1-dependent activation of EGFR and G protein-dependent activation of PKA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959465      PMCID: PMC3000948          DOI: 10.1074/jbc.M110.117689

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  Regulation of tyrosine kinase cascades by G-protein-coupled receptors.

Authors:  L M Luttrell; Y Daaka; R J Lefkowitz
Journal:  Curr Opin Cell Biol       Date:  1999-04       Impact factor: 8.382

Review 2.  Transduction of receptor signals by beta-arrestins.

Authors:  Robert J Lefkowitz; Sudha K Shenoy
Journal:  Science       Date:  2005-04-22       Impact factor: 47.728

3.  Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor.

Authors:  Sung-Hee Chang; Catherine H Liu; Ming-Tao Wu; Timothy Hla
Journal:  Prostaglandins Other Lipid Mediat       Date:  2005-03-17       Impact factor: 3.072

Review 4.  Turning off the signal: desensitization of beta-adrenergic receptor function.

Authors:  W P Hausdorff; M G Caron; R J Lefkowitz
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

5.  Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis.

Authors:  A P Pentland; P Needleman
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

6.  Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor.

Authors:  Taghrid B El-Abaseri; Jill Fuhrman; Carol Trempus; Igor Shendrik; Raymond W Tennant; Laura A Hansen
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

7.  The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia.

Authors:  Sung-Hee Chang; Youxi Ai; Richard M Breyer; Timothy F Lane; Timothy Hla
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

8.  beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation.

Authors:  D A Conner; M A Mathier; R M Mortensen; M Christe; S F Vatner; C E Seidman; J G Seidman
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

9.  Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development.

Authors:  You Me Sung; Guobin He; Susan M Fischer
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

10.  Mechanism of biological synergy between cellular Src and epidermal growth factor receptor.

Authors:  D A Tice; J S Biscardi; A L Nickles; S J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more
  25 in total

1.  β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition.

Authors:  Yi-Xin Zhang; Xiao-Fang Li; Guo-Qiang Yuan; Hui Hu; Xiao-Yun Song; Jing-Yi Li; Xiao-Kang Miao; Tian-Xiong Zhou; Wen-Le Yang; Xiao-Wei Zhang; Ling-Yun Mou; Rui Wang
Journal:  J Biol Chem       Date:  2017-03-24       Impact factor: 5.157

2.  Discovery of G Protein-Biased EP2 Receptor Agonists.

Authors:  Seiji Ogawa; Toshihide Watanabe; Isamu Sugimoto; Kazumi Moriyuki; Yoshikazu Goto; Shinsaku Yamane; Akio Watanabe; Kazuma Tsuboi; Atsushi Kinoshita; Hideo Kigoshi; Kousuke Tani; Toru Maruyama
Journal:  ACS Med Chem Lett       Date:  2016-01-04       Impact factor: 4.345

3.  PGE2 /EP4 receptor attenuated mucosal injury via β-arrestin1/Src/EGFR-mediated proliferation in portal hypertensive gastropathy.

Authors:  Siwei Tan; Xiaoliang Chen; Minyi Xu; Xiaoli Huang; Huiling Liu; Jie Jiang; Yu Lu; Xiaojie Peng; Bin Wu
Journal:  Br J Pharmacol       Date:  2017-03-25       Impact factor: 8.739

Review 4.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

5.  Fungal pattern receptors down-regulate the inflammatory response by a cross-inhibitory mechanism independent of interleukin-10 production.

Authors:  Mario Rodríguez; Saioa Márquez; Juan Vladimir de la Rosa; Sara Alonso; Antonio Castrillo; Mariano Sánchez Crespo; Nieves Fernández
Journal:  Immunology       Date:  2016-11-09       Impact factor: 7.397

6.  Phosphorylation barcode-dependent signal bias of the dopamine D1 receptor.

Authors:  Ali I Kaya; Nicole A Perry; Vsevolod V Gurevich; T M Iverson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-05       Impact factor: 11.205

7.  Mechanotransduction signaling in podocytes from fluid flow shear stress.

Authors:  Tarak Srivastava; Hongying Dai; Daniel P Heruth; Uri S Alon; Robert E Garola; Jianping Zhou; R Scott Duncan; Ashraf El-Meanawy; Ellen T McCarthy; Ram Sharma; Mark L Johnson; Virginia J Savin; Mukut Sharma
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-06

Review 8.  Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models.

Authors:  Christina E Swan; Richard M Breyer
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-27       Impact factor: 3.072

Review 9.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

10.  EP1 disruption attenuates end-organ damage in a mouse model of hypertension.

Authors:  Christina S Bartlett; Kelli L Boyd; Raymond C Harris; Roy Zent; Richard M Breyer
Journal:  Hypertension       Date:  2012-09-24       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.